DelveInsight’s “IgA Nephropathy Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the IgA Nephropathy Pipeline? Click here to explore the therapies and trials making headlines @ IgA Nephropathy Pipeline Outlook Report
Key Takeaways from the IgA Nephropathy Pipeline Report
Want to know which companies are leading innovation in IgA Nephropathy? Dive into the full pipeline insights @ IgA Nephropathy Clinical Trials Assessment
The IgA Nephropathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The IgA Nephropathy Pipeline Report also highlights the unmet needs with respect to the IgA Nephropathy.
IgA Nephropathy Overview
IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. This condition most often occurs in Caucasian and Asian males. It usually appears when people are in their teens to late 30s but can occur at any age. Many cases resolve over time. However, in a subset of patients, the disease may not resolve and thus can lead to end-stage renal disease (ESRD) after 20-25 years. Rarely the condition can progress much more rapidly leading to renal failure within a few years, if not treated.
IgA Nephropathy Emerging Drugs Profile
Atrasentan is a potent and selective inhibitor of the endothelin A receptor (ETA) that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Chinook selected IgAN as the lead indication for atrasentan due to the role of ETA activation in driving proteinuria, mesangial cell activation, kidney inflammation and fibrosis, the hallmarks of IgAN disease progression. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of IgA Nephropathy.
SHR-2010 is a drug being studied for the treatment of Primary IgA Nephropathy. It is an injection developed by Guangdong Hengrui Pharmaceutical Co., Ltd., currently in Phase II of research. The drug is aimed at inhibiting MASP2protein. Clinical trials are ongoing to evaluate the efficacy, safety, and pharmacokinetics of SHR-2010 in patients with Primary IgA Nephropathy.
TAK-079, also known as mezagitamab, targets CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells, leading to their depletion. The rationale for using TAK-079 in IgA nephropathy is that by reducing plasma cells responsible for producing the abnormal IgA1 protein, it may help prevent the formation of pathogenic immune complexes and subsequent kidney injury. In a Phase 1b clinical trial, TAK-079 is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.
If you’re tracking ongoing IgA Nephropathy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ IgA Nephropathy Treatment Drugs
The IgA Nephropathy Pipeline report provides insights into:-
IgA Nephropathy Companies
Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals and others.
IgA Nephropathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
IgA Nephropathy Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the IgA Nephropathy Pipeline Report covers it all – check it out now @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives
Scope of the IgA Nephropathy Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the IgA Nephropathy Treatment landscape in this detailed analysis @ IgA Nephropathy Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight
